Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Formula Best Effort Presumption Is Built Into Exclusivity - Botstein

Executive Summary

The expectation that drug manufacturers will use their best efforts to develop pediatric formulations is "built in" to FDA's pediatric exclusivity presumptions, former FDA Office of Drug Evaluation III Director Paula Botstein, MD, said June 3 at a Barnett Pediatric Drug Development meeting in Philadelphia, Pa.

You may also be interested in...

Pediatric Depression Claim Requires Two Efficacy Studies - Sample Request

A drug claim for depression in children and adolescents would require two full-scale efficacy studies, a June 29 FDA sample written request for antidepressant pediatric studies states.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts